Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC.PBYI · Entity 5478 | Chief Commercial Officer | February 07, 2025 | February 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PUMA BIOTECHNOLOGY, INC.
Report date February 07, 2025 · Filed February 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 156,792 |
Reported balance
After 2025-02-07 transaction · row 1
1 source rowRow 1 · 2025-02-07 · Grant · Acquired 47,841 · Balance 156,792 F1: Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2025, January 1, 2026, July 1, 2026 and January 1, 2027, subject to the Grantee's continued service with the Company through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.78 · Expires 2035-02-06 | Direct | 66,221 |
Reported balance
After 2025-02-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-07 · Grant · Acquired 66,221 · Balance 66,221 F2: Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2025, January 1, 2026, July 1, 2026 and January 1, 2027, subject to the Optionee's continued service with the Company through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2025, January 1, 2026, July 1, 2026 and January 1, 2027, subject to the Grantee's continued service with the Company through the applicable vesting date.
F2: Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2025, January 1, 2026, July 1, 2026 and January 1, 2027, subject to the Optionee's continued service with the Company through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 07, 2025 Filed Feb 11, 2025 18:55 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 66,221 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001437749-25-003459 · rdgdoc.xml · derivative · entry 2 Ludwig Jeffrey Jerome · CIK 0001807133 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,221 Underlying: Common Stock · 66,221 shares Expires 2035-02-06 F2 · derivative.exercise_date: Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2025, January 1, 2026, July 1, 2026 and January 1, 2027, subject to the Optionee's continued service with the Company through the applicable vesting date. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 18:55 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 47,841 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-003459 · rdgdoc.xml · nonDerivative · entry 1 Ludwig Jeffrey Jerome · CIK 0001807133 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,792 F1 · shares: Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2025, January 1, 2026, July 1, 2026 and January 1, 2027, subject to the Grantee's continued service with the Company through the applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 19:31 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 9,437 | $3.15 | $29,742.59 |
DisclosureSEC source: 0001437749-25-000363 · rdgdoc.xml · nonDerivative · entry 1 Ludwig Jeffrey Jerome · CIK 0001807133 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,951 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.11 to $3.2101, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 17, 2024 Filed Jul 18, 2024 19:06 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 2,598 | $3.70 | $9,615.46 |
DisclosureSEC source: 0001437749-24-023020 · rdgdoc.xml · nonDerivative · entry 1 Ludwig Jeffrey Jerome · CIK 0001807133 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,388 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.6001 to $3.8901, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 02, 2024 Filed Jul 2, 2024 21:19 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 6,051 | $3.27 | $19,777.69 |
DisclosureSEC source: 0001437749-24-022065 · rdgdoc.xml · nonDerivative · entry 1 Ludwig Jeffrey Jerome · CIK 0001807133 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,986 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.2601 to $3.3101, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 18:00 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 37,466 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001437749-24-004214 · rdgdoc.xml · derivative · entry 2 Ludwig Jeffrey Jerome · CIK 0001807133 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,466 Underlying: Common Stock · 37,466 shares Expires 2034-02-11 F2 · derivative.exercise_date: Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2024, January 1, 2025, July 1, 2025 and January 1, 2026, subject to the Optionee's continued service with the Company through the applicable vesting date. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 18:00 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,067 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-004214 · rdgdoc.xml · nonDerivative · entry 1 Ludwig Jeffrey Jerome · CIK 0001807133 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,037 F1 · shares: Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2024, January 1, 2025, July 1, 2025 and January 1, 2026, subject to the Grantee's continued service with the Company through the applicable vesting date. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 19:00 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 12,956 | $4.49 | $58,119.32 |
DisclosureSEC source: 0001437749-24-000773 · rdgdoc.xml · nonDerivative · entry 1 Ludwig Jeffrey Jerome · CIK 0001807133 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,970 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.3601 to $4.7101, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 19:08 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 12,103 | $3.31 | $40,075.45 |
DisclosureSEC source: 0001437749-23-019523 · rdgdoc.xml · nonDerivative · entry 1 Ludwig Jeffrey Jerome · CIK 0001807133 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,926 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.24 to $3.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 16:50 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 93,028 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001437749-23-003379 · rdgdoc.xml · derivative · entry 2 Ludwig Jeffrey Jerome · CIK 0001807133 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,028 Underlying: Common Stock · 93,028 shares Expires 2033-02-09 F2 · derivative.exercise_date: Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2023, January 1, 2024, July 1, 2024 and January 1, 2025, subject to the Optionee's continued service with the Company through the applicable vesting date. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 16:50 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 66,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-003379 · rdgdoc.xml · nonDerivative · entry 1 Ludwig Jeffrey Jerome · CIK 0001807133 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,029 F1 · shares: Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2023, January 1, 2024, July 1, 2024 and January 1, 2025, subject to the Grantee's continued service with the Company through the applicable vesting date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 17:36 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 6,568 | $4.18 | $27,440.45 |
DisclosureSEC source: 0001437749-23-000534 · rdgdoc.xml · nonDerivative · entry 1 Ludwig Jeffrey Jerome · CIK 0001807133 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,057 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.13 to $4.1922, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 20:17 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 5,835 | $2.63 | $15,354.80 |
DisclosureSEC source: 0001437749-22-016848 · rdgdoc.xml · nonDerivative · entry 1 Ludwig Jeffrey Jerome · CIK 0001807133 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,625 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.60 to $2.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 03, 2022 Filed Mar 15, 2022 13:37 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 55,882 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001437749-22-006268 · rdgdoc.xml · derivative · entry 2 Ludwig Jeffrey Jerome · CIK 0001807133 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,882 Underlying: Common Stock · 55,882 shares Expires 2032-03-02 F2 · derivative.exercise_date: Subject to the Optionee's continued service with the Company through the applicable vesting date, the Option shall vest and become exercisable with respect to one-fourth (1/4th) of the Shares subject thereto on each of July 1, 2022, January 1, 2023, July 1, 2023 and January 1, 2024. Read SEC document |
| March 03, 2022 Filed Mar 15, 2022 13:37 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 39,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-006268 · rdgdoc.xml · nonDerivative · entry 1 Ludwig Jeffrey Jerome · CIK 0001807133 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,460 F1 · shares: Subject to the Grantee's continued service with the Company through the applicable vesting date, the Restricted Stock Units shall vest with respect to one-fourth (1/4th) of the Restricted Stock Units on each of July 1, 2022, January 1, 2023, July 1, 2023 and January 1, 2024. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 20:32 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 4,727 | $3.20 | $15,121.20 |
DisclosureSEC source: 0001437749-22-000498 · rdgdoc.xml · nonDerivative · entry 1 Ludwig Jeffrey Jerome · CIK 0001807133 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,342 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.17 to $3.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 19:25 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 50,740 | $0.00 Strike: $12.02 | $0.00 |
DisclosureSEC source: 0001209191-21-012573 · doc4.xml · derivative · entry 2 Ludwig Jeffrey Jerome · CIK 0001807133 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,740 Underlying: COMMON STOCK · 50,740 shares Expires 2031-02-26 F2 · shares: Subject to the Optionee's continued service with the Company through the applicable vesting date, the Option shall vest and become exercisable with respect to (i) one-third (1/3) of the Shares (as defined in the Plan) underlying the Option on the vesting commencement date of January 1, 2021 (the "Vesting Commencement Date") and (ii) one-sixth (1/6th) of the Shares subject thereto on each of July 1, 2022, January 1, 2023, July 1, 2023, and January 1, 2024. F2 · derivative.exercise_date: Subject to the Optionee's continued service with the Company through the applicable vesting date, the Option shall vest and become exercisable with respect to (i) one-third (1/3) of the Shares (as defined in the Plan) underlying the Option on the vesting commencement date of January 1, 2021 (the "Vesting Commencement Date") and (ii) one-sixth (1/6th) of the Shares subject thereto on each of July 1, 2022, January 1, 2023, July 1, 2023, and January 1, 2024. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 19:25 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 36,069 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-012573 · doc4.xml · nonDerivative · entry 1 Ludwig Jeffrey Jerome · CIK 0001807133 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,069 F1 · shares: Subject to the Grantee's continued service with the Company through the applicable vesting date, the Restricted Stock Units shall vest with respect to (i) one-third (1/3) of the Restricted Stock Units on the vesting commencement date of January 1, 2021 (the "Vesting Commencement Date") and (ii) one-sixth (1/6th) of the Restricted Stock Units on each of July 1, 2022, January 1, 2023, July 1, 2023 and January 1, 2024. Read SEC document |
| February 17, 2021 Filed Feb 23, 2021 16:24 UTC Amendment | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 36,069 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013211 · doc4a.xml · nonDerivative · entry 1 Ludwig Jeffrey Jerome · CIK 0001807133 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,069 F1 · shares: Subject to the Grantee's continued service with the Company through the applicable vesting date, the Restricted Stock Units shall vest with respect to (i) one-third (1/3) of the Restricted Stock Units on the first anniversary of the vesting commencement date of January 1, 2021 (the "Vesting Commencement Date") and (ii) one-sixth (1/6th) of the Restricted Stock Units on each of July 1, 2022, January 1, 2023, July 1, 2023 and January 1, 2024. Read SEC document |
| March 20, 2020 Filed Mar 23, 2020 19:47 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 320,000 | $0.00 Strike: $7.82 | $0.00 |
DisclosureSEC source: 0001209191-20-020763 · doc4.xml · derivative · entry 1 Ludwig Jeffrey Jerome · CIK 0001807133 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,000 Underlying: COMMON STOCK · 320,000 shares Expires 2030-03-19 F1 · derivative.exercise_date: The vesting commencement date of the option is March 16, 2020 ("Option Vesting Commencement Date"). The option vests (i) with respect to one-third (1/3rd) of the shares subject thereto on the first anniversary of the Option Vesting Commencement Date and (ii) with respect to 1/36th of the shares subject thereto on each monthly anniversary of the Option Vesting Commencement Date thereafter, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.